C4 Therapeutics, Inc.
CCCC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662579
No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 147 institutions reported holding it in 13F filings for Q2 2026, worth $547.6M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in C4 Therapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 97
- −5 vs. Q2 2025
- Shares held
- 52.5M
- −2.15M (−3.9%) vs. Q2 2025
- Total value
- $116.6M
- +$38.4M (+49.1%) vs. Q2 2025
- New holders
- 21
- 26 more added
- Sold out
- 26
- 38 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CCCC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 147 | $547.6M |
| Q1 2026 | 123 | $221.3M |
| Q4 2025 | 101 | $152.5M |
| Q3 2025 | 97 | $116.6M |
| Q2 2025 | 102 | $78.2M |
| Q1 2025 | 115 | $102.6M |
| Q4 2024 | 113 | $231.8M |
| Q3 2024 | 118 | $365.9M |
| Q2 2024 | 115 | $281.3M |
| Q1 2024 | 106 | $475.6M |
| Q4 2023 | 92 | $265.6M |
| Q3 2023 | 84 | $64.5M |
| Q2 2023 | 100 | $94.1M |
| Q1 2023 | 121 | $117.5M |
| Q4 2022 | 117 | $231.4M |
| Q3 2022 | 114 | $345.9M |
| Q2 2022 | 113 | $297.2M |
| Q1 2022 | 125 | $904.8M |
| Q4 2021 | 119 | $1.15B |
| Q3 2021 | 113 | $1.54B |
| Q2 2021 | 107 | $1.21B |
| Q1 2021 | 83 | $926.8M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding C4 Therapeutics, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jain Global LLC | 0 | $0 | 0.00% | −136,219−100.0% | Sold out |
| Aster Capital Management (DIFC) Ltd | 0 | $0 | 0.00% | −77,734−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −71,106−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −52,521−100.0% | Sold out |
| Brookstone Capital Management | 0 | $0 | 0.00% | −29,325−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −24,377−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −24,200−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −21,476−100.0% | Sold out |
| Ieq Capital, LLC | 0 | $0 | 0.00% | −18,822−100.0% | Sold out |
| Hudson Bay Capital Management LP | 0 | $0 | 0.00% | −16,095−100.0% | Sold out |
| DRW Securities, LLC | 0 | $0 | 0.00% | −15,836−100.0% | Sold out |
| Quadrature Capital Ltd | 0 | $0 | 0.00% | −13,547−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −10,963−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −11,000−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −10,589−100.0% | Sold out |
| Clear Street Markets LLC | 0 | $0 | 0.00% | −2,122−100.0% | Sold out |
| Syntax Research, Inc. | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Fortitude Family Office, LLC | 0 | $0 | 0.00% | −325−100.0% | Sold out |
| EverSource Wealth Advisors, LLC | 0 | $0 | 0.00% | −310−100.0% | Sold out |
| Skopos Labs, Inc. | 0 | $0 | 0.00% | −295−100.0% | Sold out |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −135−100.0% | Sold out |
| Essential Partners LLC | 0 | $0 | 0.00% | −133−100.0% | Sold out |
| True Wealth Design, LLC | 0 | $0 | 0.00% | −31−100.0% | Sold out |